Retatrutide cuts weight 25% at 12 mg in Phase 3 NEJM trial
Roughly 11% of patients on the top dose stopped treatment for adverse events, against 4.6% on placebo, with nausea reported by about 42%.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 3 03:55 ETSource: NDTV
The wire
- 01In 2,339 adults with obesity and without diabetes, 80-week weight loss averaged 25% on 12 mg, 23.7% on 9 mg and 17.6% on 4 mg versus 3.9% on placebo.
- 02The triple GLP-1/GIP/glucagon agonist also reduced knee osteoarthritis pain and cut sleep apnoea breathing disruptions by 32.1 events per hour at the top dose, relevant to comorbidity-driven prescribing.
- 03A 532-patient extension reached 29.9% loss at 104 weeks but was not a placebo-controlled two-year comparison; the trial was Lilly-funded, had no cardiovascular safety design and no head-to-head against semaglutide or tirzepatide.
From the source
Read at ndtv.comOzempic Rival Retatrutide Delivers 25% Weight Loss In Phase 3 Trial
An experimental weight-loss injection has helped people with obesity lose an average of up to 25 per cent of their body weight at the highest dose, according to results from a large Phase 3 clinical trial. The drug, called retatrutide, is being developed by Eli Lilly. Researchers studied 2,339 adults with obesity who did not have diabetes. Participants were given weekly injections of 4 mg, 9 mg or
